Key clinical point: Clinical risk stratification adds prognostic value to the 21-gene RS in early breast cancer.
Major finding: Among women over age 50 years, the hazard ratios for distant recurrence ranged from 2.20 to 2.36.
Study details: A secondary analysis of data from 9,427 patients from the TAILORx trial.
Disclosures: TAILORx was funded by the National Institutes of Health. Dr. Sparano reported stock ownership, a consulting role, and research funding from several pharmaceutical companies. Dr. Stearns reported consulting or advisory roles with Iridium Therapeutics; research funding from Abbvie, Biocept, MedImmune, Novartis, Pfizer, and Puma Biotechnology; and an “other relationship” with Immunomedics.
Sparano JA et al. ASCO 2019. Abstract 503.